10157702The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme [Extension]ClosedInvestment AcceleratorInnovate UKThe DEVOTE programme is helping to bring cutting-edge genetic testing into everyday healthcare in Greater Manchester. By combining expertise from universities, hospitals, and businesses, it has already started improving patient care by making genetic testing a routine part of diagnosis and treatment. The next phase of DEVOTE will continue working with industry partners to develop and commercialise new genetic testing technologies. This will help bring medical breakthroughs to patients faster and support business growth in the region. The DEVOTE extension will work with four industry partners (Genedrive, EMQN, APIS Assay Ltd and Chromition) to expand on the excellent work already undertaken. These exemplar projects will: * Develop a rapid test capable of detecting high-risk genetic changes which are known to predispose to aminoglycoside induced hearing loss (AIHL). * Create software tools to allow genetic tests to communicate with the electronic healthcare record (EHR). * To create ultrarapid detection systems to help identify and treat infection * To improve methods by which genetic tests can be validated, promoting their use internationally. Locally, DEVOTE strengthens Greater Manchester's reputation as a hub for genetic innovation, attracting companies and investment. Nationally, it supports the UK's goals of turning research into real-world benefits and building a more proactive, prevention-focused NHS.